Do all patients that undergo a ‘complete’ secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it?
– Selection criteria used in all three randomized trials are predictive of a complete cytoreduction and not the benefit of surgery– Post-hoc & prespecified subgroup analyses indicate that not all patients undergoing secondary cytoreduction benefit from it– Post-hoc and sub-group analysis should...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2024-07-01
|
| Series: | Pleura and Peritoneum |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/pp-2023-0052 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846162261324857344 |
|---|---|
| author | Bhatt Aditi Mehta Sanket Glehen Olivier |
| author_facet | Bhatt Aditi Mehta Sanket Glehen Olivier |
| author_sort | Bhatt Aditi |
| collection | DOAJ |
| description | – Selection criteria used in all three randomized trials are predictive of a complete cytoreduction and not the benefit of surgery– Post-hoc & prespecified subgroup analyses indicate that not all patients undergoing secondary cytoreduction benefit from it– Post-hoc and sub-group analysis should be performed separately for patients undergoing a complete gross resection– Impact of incomplete cytoreduction on quality of life and subsequent therapy needs further evaluation– Future randomized trials should use surgical prognostic factors like disease sites and extent as stratification factors |
| format | Article |
| id | doaj-art-ba8a41f2e1224d9a9a49f2718c7ef132 |
| institution | Kabale University |
| issn | 2364-768X |
| language | English |
| publishDate | 2024-07-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Pleura and Peritoneum |
| spelling | doaj-art-ba8a41f2e1224d9a9a49f2718c7ef1322024-11-20T15:35:51ZengDe GruyterPleura and Peritoneum2364-768X2024-07-01939310510.1515/pp-2023-0052Do all patients that undergo a ‘complete’ secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it?Bhatt Aditi0Mehta Sanket1Glehen Olivier2Department of Surgical Oncology, KD Hospital, Ahmedabad, IndiaDepartment of Surgical Oncology, Saifee Hospital, Mumbai, IndiaDepartment of Surgical Ocology, Centre Hospitalier Lyon-sud, Lyon, France– Selection criteria used in all three randomized trials are predictive of a complete cytoreduction and not the benefit of surgery– Post-hoc & prespecified subgroup analyses indicate that not all patients undergoing secondary cytoreduction benefit from it– Post-hoc and sub-group analysis should be performed separately for patients undergoing a complete gross resection– Impact of incomplete cytoreduction on quality of life and subsequent therapy needs further evaluation– Future randomized trials should use surgical prognostic factors like disease sites and extent as stratification factorshttps://doi.org/10.1515/pp-2023-0052recurrent ovarian cancerplatinum-sensitive recurrencesecondary cytoreductive surgerypatient selection |
| spellingShingle | Bhatt Aditi Mehta Sanket Glehen Olivier Do all patients that undergo a ‘complete’ secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it? Pleura and Peritoneum recurrent ovarian cancer platinum-sensitive recurrence secondary cytoreductive surgery patient selection |
| title | Do all patients that undergo a ‘complete’ secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it? |
| title_full | Do all patients that undergo a ‘complete’ secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it? |
| title_fullStr | Do all patients that undergo a ‘complete’ secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it? |
| title_full_unstemmed | Do all patients that undergo a ‘complete’ secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it? |
| title_short | Do all patients that undergo a ‘complete’ secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it? |
| title_sort | do all patients that undergo a complete secondary cytoreductive surgery for platinum sensitive recurrent ovarian cancer benefit from it |
| topic | recurrent ovarian cancer platinum-sensitive recurrence secondary cytoreductive surgery patient selection |
| url | https://doi.org/10.1515/pp-2023-0052 |
| work_keys_str_mv | AT bhattaditi doallpatientsthatundergoacompletesecondarycytoreductivesurgeryforplatinumsensitiverecurrentovariancancerbenefitfromit AT mehtasanket doallpatientsthatundergoacompletesecondarycytoreductivesurgeryforplatinumsensitiverecurrentovariancancerbenefitfromit AT glehenolivier doallpatientsthatundergoacompletesecondarycytoreductivesurgeryforplatinumsensitiverecurrentovariancancerbenefitfromit |